Exhibit,Appendix: Cresco Labs New York, Llc, a New York limited liability company, Cresco Labs Llc, An Illinois Limited Liability Company v. Fiorello Pharmaceuticals, Inc., a New York corporation, Eric Sirota, Susan Yoss, John Does 1 - 10

• 
• 
• 
• 

						
                                
Preview
                                FILED:         NEW     YORK       COUNTY        CLERK        01/20/2022             01:52        PM                 INDEX    NO.   652343/2018
   NYSCEF     DOC.   NO.   662                                                                                RECEIVED      NYSCEF:     01/20/2022




                                                                  Exhibit        RR

                                                  October 5, 2018 Letter From DOH
                       Setting January 31, 2019 Deadline For Fiorello To Become Operational




                  Index No. 652343/2018                                                                        Motion Seq. No. 12
   FILED:         NEW     YORK       COUNTY        CLERK        01/20/2022             01:52        PM                 INDEX    NO.   652343/2018
   NYSCEF     DOC.   NO.   662                                                                                RECEIVED      NYSCEF:     01/20/2022

                            WYORK
                            JEOF
                                           Department
                            ORTUNITY.
                                           of   Health
            ANDREW M. CUOMO                               HOWARD A. ZUCKER, M.D., J.D.                  SALLY DRESLIN, M.S., R.N.
            Governor                                      Commissioner                                  Executive Deputy Commissioner




                                                                            October 5, 2018

             VIA CERTIFIED AND ELECTRONIC MAIL to eric@fpnys.com


             Mr. Eric Sirota
             Fiorello Pharmaceuticals, Inc.
             12 East 49th Street, 11th Floor
             New York, NY 10017

             Dear Mr. Sirota:

                       Pursuant to 10 NYCRR § 1004.9, if a registered organization fails to begin operations, to the
             satisfaction of the Department, of a manufacturing or dispensing facility within six months of the date of
             issuance of the registration, it is required to surrender its registration to the Department of Health
             (Department) upon written notice and demand. To date, the Department has been very flexible in allowing
             Fiorello Pharmaceuticals, Inc. additional time to begin operations.              Fiorello Pharmaceuticals, Inc. however,
             was issued a registration on August 1, 2017 and has yet to begin operations.                   This letter serves as written
             notice to Fiorello Pharmaceuticals, Inc. that it must begin operations, to the satisfaction of the Department,
             by January 31, 2019.

                      To begin operations to the satisfaction of the Department, and avoid surrender of your registration,
             Fiorello Pharmaceuticals, Inc. must, at a minimum, have two operational dispensing facilities and
             begin manufacturing within six months prior to the expiration of its registration.

                      In addition, please be aware that 10 NYCRR § 1004.7(a) requires Fiorello Pharmaceuticals, Inc. to
             file an application for renewal to the Department four to six months prior to the expiration of its registration
             on July 31, 2019.      As of right now, there is insufficient criteria to justify renewing Fiorello Pharmaceuticals,
             Inc.’s registration, since Fiorello Pharmaceuticals, Inc. does not have any operational facilities.

                      Please submit a confirmatory email to ROCommunications@health.ny.gov to acknowledge receipt of
             this letter and provide a weekly written narrative documenting Fiorello Pharmaceuticals, Inc.’s specific
             progress toward meeting the requirements listed above to begin operations beginning 1/31/19. Should you
             have any questions concerning this letter, please contact me directly at (518) 402-0705.

                                                                   Sincerely,



                                                                   Nicole K. Quackenbush, Pharm.D.
                                                                   Director
                                                                   Medical Marijuana Program




                                              Empire State Plaza, Corning Tower, Albany, NY 12237 J health.ny.gov